Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder

Mallik Greene, Tingjian Yan, Eunice Chang, +3

Journal of Medical Economics

Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia

Rachel Halpern, Jerald Seare, Junliang Tong, +3

International Journal of Geriatric Psychiatry

Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

Dana DiBenedetti, Christina Slota, Samantha L. Wronski, +14

Alzheimer s Research & Therapy

Chronic Pain and Pain Medication Use in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study

Melissa Roberts, Douglas W. Mapel, Ann Hartry, +2

Annals of the American Thoracic Society

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

Myrlene Sanon Aigbogun, Robert Stellhorn, Ann Hartry, +2

BMC Neurology

Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

Tingjian Yan, Mallik Greene, Eunice Chang, +3

Advances in Therapy

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients

Nawal Bent‐Ennakhil, F Coste, Lin Xie, +7

Neurology and Therapy

Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia

Annalisa Rubino, Myrlene Sanon, Michael L. Ganz, +8

JAMA Network Open

Institutionalization risk and costs associated with agitation in Alzheimer's disease

Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, +6

Alzheimer s & Dementia Translational Research & Clinical Interventions

Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics

Joanna P. MacEwan, Siddhesh Kamat, Ruth A. Duffy, +6

Psychiatric Services